Senseonics Holdings (NYSEMKT:SENS) is up 7.9% today after it reported publishing data on its Eversense continuous glucose monitoring system.
The company evaluated the system from June 2016 to August 2019, it says in the journal Diabetes Technology and Therapeutics.
It covered 945 adult users in the home setting and demonstrated the performance of the sensor over four sensor cycles was stable and didn’t decrease over time, as well as showing no degradation of patient glucose outcomes.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.